Evaluating the potential clinical benefits of switching patients with plaque psoriasis from calcipotriene to tazarotene treatment.

Abstract

Overall results from a multicenter study involving more than 1000 patients with plaque psoriasis treated with tazarotene 0.1% gel plus a topical corticosteroid are soon to be published. This report considers a subgroup of 246 patients from that study who were switched from calcipotriene plus corticosteroid treatment (at baseline) to tazarotene plus corticosteroid for up to 12 weeks. Moderate (> or = 50%) global improvement was achieved in 75% of patients between the baseline visit (when on calcipotriene therapy) and the final visit (when on tazarotene therapy). Considerable additional reductions (38%-50%) in overall severity of plaque psoriasis, plaque elevation, scaling, pruritus, and overall discomfort were achieved over and above improvements already achieved with calcipotriene therapy. Furthermore, 74% of patients were satisfied with their treatment regimen at the final visit (when on tazarotene therapy), compared with 17% at baseline (when on calcipotriene therapy).

• Authors: D Coynik
• Journal: Cutis (Cutis) Vol. 66 Issue 6 Suppl Pg. 19-24 (Dec 2000) ISSN: 0011-4162 [Print] United States
• PMID: 11147087 (Publication Type: Clinical Trial, Comparative Study, Evaluation Study, Journal Article, Multicenter Study)

Chemical References

• Anti-Inflammatory Agents
• Dermatologic Agents
• Glucocorticoids
• Nicotinic Acids
• calcipotriene
• tazarotene
• Calcitriol

Topics

• Administration, Topical
• Anti-Inflammatory Agents (therapeutic use)
• Calcitriol (analogs & derivatives, therapeutic use)
• Dermatologic Agents (therapeutic use)
• Drug Therapy, Combination
• Female
• Glucocorticoids
• Humans
• Male
• Middle Aged
• Nicotinic Acids (therapeutic use)
• Patient Satisfaction
• Psoriasis (drug therapy)
• Severity of Illness Index
• Treatment Outcome